88 related articles for article (PubMed ID: 2572301)
1. Dynorphin A(1-13) modulates apomorphine-induced behaviors using multidimensional behavioral analyses in the mouse.
Ukai M; Toyoshi T; Kameyama T
Brain Res; 1989 Oct; 499(2):299-304. PubMed ID: 2572301
[TBL] [Abstract][Full Text] [Related]
2. Receptor-selective opioid peptides fail to affect behavioral responses induced by a low dose of apomorphine in the mouse.
Ukai M; Toyoshi T; Kameyama T
Pharmacol Biochem Behav; 1993 Nov; 46(3):587-91. PubMed ID: 7904071
[TBL] [Abstract][Full Text] [Related]
3. Intrastriatal injection of opioid receptor agonists inhibits apomorphine-induced behavior in 6-hydroxydopamine-treated mice.
Toyoshi T; Ukai M; Kameyama T
Eur J Pharmacol; 1995 Dec; 294(2-3):637-43. PubMed ID: 8750728
[TBL] [Abstract][Full Text] [Related]
4. Multidimensional behavioral analyses show dynorphin A-(1-13) modulation of methamphetamine-induced behaviors in mice.
Ukai M; Toyoshi T; Kameyama T
Eur J Pharmacol; 1992 Nov; 222(1):7-12. PubMed ID: 1361442
[TBL] [Abstract][Full Text] [Related]
5. Opioid receptor agonists selective for mu and kappa receptors attenuate methamphetamine-induced behavioral sensitization in the mouse.
Toyoshi T; Ukai M; Kameyama T
Biol Pharm Bull; 1996 Mar; 19(3):369-74. PubMed ID: 8924903
[TBL] [Abstract][Full Text] [Related]
6. Dynorphin A(1-13) preferentially inhibits behaviors induced by the D2 dopamine agonist RU 24213 but not by the D1 dopamine agonist SK&F 38393.
Ukai M; Toyoshi T; Kameyama T
Pharmacol Biochem Behav; 1992 Aug; 42(4):755-9. PubMed ID: 1355296
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of dynorphin A(1-13) markedly inhibits different behavioural responses induced by cocaine in the mouse.
Ukai M; Kamiya T; Toyoshi T; Kameyama T
Neuropharmacology; 1992 Sep; 31(9):843-9. PubMed ID: 1359442
[TBL] [Abstract][Full Text] [Related]
8. Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice.
Ukai M; Mizutani M; Kameyama T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1994 Jun; 14(3):153-9. PubMed ID: 7941780
[TBL] [Abstract][Full Text] [Related]
9. DAGO ([D-Ala2,N-Me-Phe4,Gly-ol]enkephalin) specifically reverses apomorphine-induced increase in rearing and grooming behaviors in the mouse.
Ukai M; Toyoshi T; Kameyama T
Brain Res; 1991 Aug; 557(1-2):77-82. PubMed ID: 1660758
[TBL] [Abstract][Full Text] [Related]
10. The antagonistic effects of naloxone on hypermotility in mice induced by dynorphin-(1-13) using a multi-dimensional behavioral analysis.
Ukai M; Kameyama T
Neuropharmacology; 1984 Feb; 23(2A):165-8. PubMed ID: 6717756
[TBL] [Abstract][Full Text] [Related]
11. Naloxone reserves the inhibitory effects of dynorphin A on motor activity in the mouse.
Ukai M; Yamada S; Kameyama T
Pharmacol Biochem Behav; 1984 May; 20(5):815-8. PubMed ID: 6146145
[TBL] [Abstract][Full Text] [Related]
12. Apparent enhancement by SCH 23390 of apomorphine-induced locomotor activity in mice.
Matsumoto K; Cai B; Ohta H; Imamura L; Watanabe H
Pharmacol Biochem Behav; 1991 Jul; 39(3):699-703. PubMed ID: 1784598
[TBL] [Abstract][Full Text] [Related]
13. Bestatin potentiates the antinociception but not the motor dysfunction induced by intracerebrally administered dynorphin-B in mice.
Nakazawa T; Ikeda M; Kaneko T; Yamatsu K; Kitagawa K; Kiso Y
Neuropeptides; 1989; 13(4):277-83. PubMed ID: 2568600
[TBL] [Abstract][Full Text] [Related]
14. Dynorphin a (1-13) alleviated stress-induced behavioral impairments in mice.
Mamiya T; Hasegawa Y; Hiramatsu M
Biol Pharm Bull; 2014; 37(8):1269-73. PubMed ID: 25087948
[TBL] [Abstract][Full Text] [Related]
15. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice.
Kuzmin A; Madjid N; Terenius L; Ogren SO; Bakalkin G
Neuropsychopharmacology; 2006 Sep; 31(9):1928-37. PubMed ID: 16292317
[TBL] [Abstract][Full Text] [Related]
16. Dynorphin A-(1-13) potently improves scopolamine-induced impairment of passive avoidance response in mice.
Ukai M; Kobayashi T; Shinkai N; Shan-Wu X; Kameyama T
Eur J Pharmacol; 1995 Feb; 274(1-3):89-93. PubMed ID: 7768285
[TBL] [Abstract][Full Text] [Related]
17. Effects of dynorphin (1-8) on movement: non-opiate effects and structure-activity relationship.
Friederich MW; Friederich DP; Walker JM
Peptides; 1987; 8(5):837-40. PubMed ID: 2893358
[TBL] [Abstract][Full Text] [Related]
18. Modulation of morphine-induced EEG and behavioral effects by dynorphin A-(1-13) in non-tolerant and morphine-tolerant rats.
Hong O; Young GA; Khazan N
Neuropharmacology; 1988 Aug; 27(8):807-12. PubMed ID: 2905786
[TBL] [Abstract][Full Text] [Related]
19. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.
Zhang Y; Butelman ER; Schlussman SD; Ho A; Kreek MJ
Psychopharmacology (Berl); 2004 Apr; 172(4):422-9. PubMed ID: 14712335
[TBL] [Abstract][Full Text] [Related]
20. Behavioral effects of d-amphetamine and apomorphine in the hamster.
Peterson ME; Morin LP
Pharmacol Biochem Behav; 1984 Jun; 20(6):855-8. PubMed ID: 6540446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
